ライフサイエンスコーパス: tranexamic acid

1 ected after hemostatic resuscitation without tranexamic acid.

2 understanding of the mechanism of action of tranexamic acid.

3 Thrombolysis was suppressed with tranexamic acid.

4 izumab 1% (4 mg/d), estriol 0.1% (0.4 mg/d), tranexamic acid 10% (40 mg/d), or placebo (0.9% saline).

5 use mortality was significantly reduced with tranexamic acid (1463 [14.5%] tranexamic acid group vs 1

6 tranexamic acid/cryoprecipitate (11.6%) and tranexamic acid (18.2%) groups compared with the cryopre

7 oic acid (-184 mL; 95% CI, -256 to -112) and tranexamic acid (-195 mL; 95% CI, -286 to -105).

8 horter than without treatment (45 h) or with tranexamic acid (38 h).

9 .03; 95% confidence interval, 0.80-1.33) nor tranexamic acid (65 deaths among 442 patients [14.7%]; a

10 1295 patients], aminocaproic acid [883], and tranexamic acid [822]) as compared with no agent (1374 p

11 rt delay in treatment reduces the benefit of tranexamic acid administration.

12 atment of AD mice with the plasmin inhibitor tranexamic acid aggravated pathology, whereas removal of

13 ologic inhibition of plasmin activation with tranexamic acid also delayed disease onset.

14 cologic inhibitor of plasminogen activation, tranexamic acid, also delays the onset of neuroinflammat

15 ient mice and in wild-type mice treated with tranexamic acid, an inhibitor of plasminogen activation.

16 10 096 patients were allocated to tranexamic acid and 10 115 to placebo, of whom 10 060 an

17 10,096 patients were allocated to tranexamic acid and 10,115 to placebo, of whom 10,060 an

18 The combined tranexamic acid and cryoprecipitate effect vs. neither i

19 Tranexamic acid and cryoprecipitate were independently a

20 -Pg contributed to cell adhesion inasmuch as tranexamic acid and epsilon-aminocaproic acid inhibited

21 apies (pdC1-INH or icatibant), 15% were with tranexamic acid, and 35% were not treated.

22 ) for acute swelling attacks and progestins, tranexamic acid, and danazol for the prevention of attac

23 the medicinal products (C1-INH concentrate, tranexamic acid, and danazol) administered for STP.

24 ve generic medications aminocaproic acid and tranexamic acid are safe alternatives.

25 sive alternatives (ie, aminocaproic acid and tranexamic acid) are available.

26 ical community by increasing awareness about tranexamic acid-associated seizures and by translating s

27 o the potential causes of and treatments for tranexamic acid-associated seizures.

28 The tranexamic acid biocompatible polymer microneedle used i

29 Tranexamic acid can reduce bleeding in patients undergoi

30 However, many clinicians are unaware that tranexamic acid causes seizures.

31 The results of the tranexamic acid comparison are reported here.

32 ll requirements, mortality was lowest in the tranexamic acid/cryoprecipitate (11.6%) and tranexamic a

33 ared with the cryoprecipitate (21.4%) and no tranexamic acid/cryoprecipitate (23.6%) groups.

34 nexamic acid (mean [SD], 23.0 [19.2]) and no tranexamic acid/cryoprecipitate (mean [SD], 21.2 [18.5])

35 cryoprecipitate (mean [SD], 28.3 [15.7]) and tranexamic acid/cryoprecipitate (mean [SD], 26 [14.9]) g

36 c acid (n = 148), cryoprecipitate (n = 168), tranexamic acid/cryoprecipitate (n = 258), and no tranex

37 xamic acid/cryoprecipitate (n = 258), and no tranexamic acid/cryoprecipitate (n = 758).

38 ation, a levonorgestrel intrauterine system, tranexamic acid (during menstrual flow), high-dose proge

39 er discontinuing eOC (16 women), 93.8% under tranexamic acid (four women), and 100% under danazol (th

40 ble outcomes data; 2311 were assigned to the tranexamic acid group and 2320 to the placebo group.

41 fused during hospitalization was 4331 in the tranexamic acid group and 7994 in the placebo group (P<0

42 tion occurred in 1.4% of the patients in the tranexamic acid group and in 2.8% of the patients in the

43 vent occurred in 386 patients (16.7%) in the tranexamic acid group and in 420 patients (18.1%) in the

44 y reduced with tranexamic acid (1463 [14.5%] tranexamic acid group vs 1613 [16.0%] placebo group; rel

45 h due to bleeding (198/3747 [5.3%] events in tranexamic acid group vs 286/3704 [7.7%] in placebo grou

46 e estriol group, 7.5 (IQR, 3.0-11.0) for the tranexamic acid group, and 8.0 (IQR, 3.0-14.0) for the p

47 0 138 patients from two randomised trials of tranexamic acid in acute severe bleeding (traumatic and

48 by calculating the diffusion coefficient of tranexamic acid in interstitial fluid (plasma).

49 independently add to the survival benefit of tranexamic acid in the seriously injured requiring trans

50 Tranexamic acid inhibited ICH expansion in uPA(-/-)mice

51 Tranexamic acid is a novel drug for treating melasma tha

52 trauma patients admitted late after injury, tranexamic acid is less effective and could be harmful.

53 Because tranexamic acid is thought to exert its effect through i

54 fferent therapies among different countries, tranexamic acid is widely available, and is an effective

55 he most commonly used antifibrinolytic drug, tranexamic acid, is associated with an increased inciden

56 omly assigned within 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min followed b

57 omly assigned within 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min then infus

58 Furthermore, there are concerns that tranexamic acid may have prothrombotic and proconvulsant

59 an [SD], 26 [14.9]) groups compared with the tranexamic acid (mean [SD], 23.0 [19.2]) and no tranexam

60 vonorgestrel-IUS or usual medical treatment (tranexamic acid, mefenamic acid, combined estrogen-proge

61 ood cells and composed the following groups: tranexamic acid (n = 148), cryoprecipitate (n = 168), tr

62 We examined the effect of tranexamic acid on death due to bleeding according to ti

63 recorded strong evidence that the effect of tranexamic acid on death due to bleeding varied accordin

64 We recorded no evidence that the effect of tranexamic acid on death due to bleeding varied by systo

65 ssess the effects of early administration of tranexamic acid on death, vascular occlusive events, and

66 of early administration of a short course of tranexamic acid on death, vascular occlusive events, and

67 al (which originally evaluated the effect of tranexamic acid on mortality in trauma patients) was con

68 Treatment delay did not modify the effect of tranexamic acid on vascular occlusive events.

69 plications to receive aspirin or placebo and tranexamic acid or placebo.

70 plications to receive aspirin or placebo and tranexamic acid or placebo.

71 Tranexamic acid or virally inactivated fresh frozen plas

72 dysfunction in patients receiving aprotinin, tranexamic acid, or no antifibrinolytic treatment in the

73 rly, inhibiting endogenous fibrinolysis with tranexamic acid reduced retraction of fibrin polymers in

74 Tranexamic acid reduces the risk of bleeding among patie

75 ion of plasmin activation and/or activity by tranexamic acid reversed both the accelerated fibrin cle

76 Tranexamic acid safely reduced the risk of death in blee

77 On the basis of these results, tranexamic acid should be considered for use in bleeding

78 Tranexamic acid should be given as early as possible to

79 Tranexamic acid significantly decreased blood transfusio

80 Tranexamic acid significantly increased overall survival

81 Tranexamic acid significantly reduced all-cause mortalit

82 ental biofilms and whether the lysine analog tranexamic acid (TA) inhibits LDC activity, biofilm accu

83 log antifibrinolytics (aminocaproic acid and tranexamic acid), the serine protease inhibitor aprotini

84 The antifibrinolytic drugs tranexamic acid (TXA) and epsilon-aminocaproic acid (EAC

85 zed trials have demonstrated the efficacy of tranexamic acid (TXA) in reducing blood loss and transfu

86 One exception is tranexamic acid (TXA), which, as a lysine mimetic, inhib

87 currently available antifibrinolytics, e.g., tranexamic acid (TXA, 1) and aprotinin, has been challen

88 sal treatment with bevacizumab vs estriol vs tranexamic acid vs placebo and epistaxis frequency.

89 Tranexamic acid was associated with a higher risk of pos

90 patients undergoing coronary-artery surgery, tranexamic acid was associated with a lower risk of blee

91 Neither aminocaproic acid nor tranexamic acid was associated with an increased risk of

92 Neither aminocaproic nor tranexamic acid was associated with increased risk of de

93 ors, including epsilon-aminocaproic acid and tranexamic acid, were effective in treating and preventi

94 equally or more effective than aprotinin or tranexamic acid, which have been used as antifibrinolyti

95 re aprotinin, epsilon-aminocaproic acid, and tranexamic acid with placebo and head to head on 8 clini

96 o increase in vascular occlusive events with tranexamic acid, with no heterogeneity by site of bleedi